Sino Biopharmaceutical Ltd.'s profit for the first quarter ended March 31 rose 11.1% year-over-year.

Profit attributable to the owners of the parent was about 856.7 million yuan, compared to 771.1 million yuan in the same period a year ago.

EPS attributable to ordinary equity holders of the parent was 6.80 fen, compared to 6.44 fen in the year-ago period.

Revenue for the Hong Kong-based drugmaker rose by 33.4% year over year to 6.21 billion yuan.

As of May 20, US$1 was equivalent to 6.91 yuan.